CommercialCoverageMedium impact
08.01.23i, Interleukin-5 (IL-5) Antagonist (e.g., Cinqair®)
Independence Blue Cross·Pulmonology, Allergy & Immunology, Internal Medicine +1 more·Pharmacy
Effective date
Jan 22, 2025
We identified it
Jun 19, 2026
Summary
IBX has reissued their policy for Interleukin-5 (IL-5) Antagonist medications like Cinqair®, effective January 22, 2025. This is a pharmacy policy update that may affect coverage criteria or prior authorization requirements for these specialty medications used to treat severe asthma.
Action Required
By January 22, 2025: Billing and clinical teams should review the updated IBX policy for IL-5 antagonist medications (Cinqair®) at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or documentation needs. Update any internal protocols for prescribing or billing these specialty asthma medications accordingly.